Rejimen KDT-ARV terbaru dengan Dolutegravir

Maria Cecilia Gritce Widjaja


Terapi HIV/AIDS terus mengalami perkembangan. Rejimen ARV terbaru saat ini menggunakan Dolutegravir dalam rejimen KDT-ARV berupa KDT-TLD, yang berisi 2NRTI + INSTI. Rejimen baru ini diteliti mampu menekan jumlah virus lebih cepat, mengurangi efek neuropsikiatri dan mengurangi resistensi pada rejimen sebelumnya yang menggunakan efavirenz. Inisiasi ARV juga disarankan sedini mungkin (jika belum ada infeksi oportunistik) supaya dapat meningkatkan harapan hidup, menurunkan insiden infeksi oportunistik, dan mencegah transmisi virus HIV.

HIV/AIDS therapy continues to develop over time. The current ARV regiment uses dolutegravir in ARV-FDC regiment in the form of a TLD-FDC containing 2NRTI + INSTI. This new regiment was intended to suppress viral load more rapidly, reduce neuropsychiatric effects and reduce resistance to previous regiments using efavirenz. ARV initiation is also recommended as early as possible (if there is no opportunistic infection) to increase life expectancy, reduce the incidence of opportunistic infections, and prevent transmission of HIV.

Full Text:



UNAIDS data. Joint United Nations Programme on HIV/AIDS. 2021.

Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/90/2019.

Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s Principles of Internal Medicine, 19 ed. Vol. 1. McGraw-Hill New York, NY, USA:; 2015.

Purnamasari D. Buku ajar ilmu penyakit dalam. Edisi Ke-6 Jakarta: Papdi. 2014;

World Health Organization. Update of recommendations on first-and second-line antiretroviral regimens. World Health Organization; 2019.

Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Medicine. 2019;16(9).

The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. 2015;373(9): 795–807.

Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in Medicine. 2012;2(4).

Aquaro S, Borrajo A, Pellegrino M, Svicher V. Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages. Virulence 2020;11:400–13.

Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinetics. 2013;52: 981–94.

Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, et al. Risks and benefits of dolutegravir- And efavirenz-based strategies for South African women with HIV of child-bearing potential. Ann Intern Med. 2019;170(9):614–25.

Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. Eclinical Med. 2020 Nov 1;28.

Raesima MM, Ogbuabo CM, Thomas V, Forhan SE, Gokatweng G, Dintwa E, et al. Dolutegravir Use at Conception — Additional Surveillance Data from Botswana. N Engl J Med. 2019;381(9):885–7.

Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Mede. 2019;381(9):827–40.

World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring : recommendations for a public health approach. 2021. p. 548.

Rekomendasi panel ahli penanggulangan HIV/AIDS dan IMS hasil rapat daring Kamis, 2 Juli 2020.

Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infection, Genetics and Evolution. Elsevier; 2016;46:292–307.

Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected with Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis. 2020;70(4):549–56.


  • There are currently no refbacks.